Literature DB >> 23754622

MicroRNA-124 protects against focal cerebral ischemia via mechanisms involving Usp14-dependent REST degradation.

Thorsten R Doeppner1, Maria Doehring, Eva Bretschneider, Anil Zechariah, Britta Kaltwasser, Barbara Müller, Jan C Koch, Mathias Bähr, Dirk M Hermann, Uwe Michel.   

Abstract

MicroRNAs (miRNAs) are highly conserved non-coding RNAs modulating gene expression via mRNA binding. Recent work suggests an involvement of miRNAs in cardiovascular diseases including stroke. As such, the brain-abundant miR-124 and its transcriptional repressor RE1-silencing transcription factor (REST) do not only have elementary roles in the developing and the adult brain, but also alter expression upon cerebral ischemia. However, the therapeutic potential of miR-124 against stroke and the mechanisms involved remain elusive. Here, we analyzed the therapeutic potential of ectopic miR-124 against stroke and its underlying mechanisms with regard to the interaction between miR-124 and REST. Our results show that viral vector-mediated miR-124 delivery increased the resistance of cultured oxygen-glucose-deprived cortical neurons in vitro and reduced brain injury as well as functional impairment in mice submitted to middle cerebral artery occlusion. Likewise, miR-124 induced enhanced neurovascular remodeling leading to increased angioneurogenesis 8 weeks post-stroke. While REST abundance increased upon stroke, the increase was prevented by miR-124 despite a so far unknown negative feedback loop between miR-124 and REST. Rather, miR-124 decreased the expression of the deubiquitinating enzyme Usp14, which has two conserved miR-124-binding sites in the 3'UTR of its mRNA, and thereby mediated reduced REST levels. The down-regulation of REST by miR-124 was also mimicked by the Usp14 inhibitor IU-1, suggesting that miR-124 promotes neuronal survival under ischemic conditions via Usp14-dependent REST degradation. Ectopic miR-124 expression, therefore, appears as an attractive and novel tool in stroke treatment, mediating neuroprotection via a hitherto unknown mechanism that involves Usp14-dependent REST degradation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23754622     DOI: 10.1007/s00401-013-1142-5

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  62 in total

1.  Traceable microRNA-124 loaded nanoparticles as a new promising therapeutic tool for Parkinson's disease.

Authors:  Cláudia Saraiva; Lino Ferreira; Liliana Bernardino
Journal:  Neurogenesis (Austin)       Date:  2016-11-14

Review 2.  The interplay of microRNAs and post-ischemic glutamate excitotoxicity: an emergent research field in stroke medicine.

Authors:  Alireza Majdi; Javad Mahmoudi; Saeed Sadigh-Eteghad; Mehdi Farhoudi; Siamak Sandoghchian Shotorbani
Journal:  Neurol Sci       Date:  2016-06-27       Impact factor: 3.307

Review 3.  Deubiquitylating enzymes in neuronal health and disease.

Authors:  Fatima Amer-Sarsour; Alina Kordonsky; Yevgeny Berdichevsky; Gali Prag; Avraham Ashkenazi
Journal:  Cell Death Dis       Date:  2021-01-22       Impact factor: 8.469

Review 4.  Epigenetic mechanisms of neuroplasticity and the implications for stroke recovery.

Authors:  Ryan J Felling; Hongjun Song
Journal:  Exp Neurol       Date:  2014-09-26       Impact factor: 5.330

5.  Identification of circulating microRNAs as potential biomarkers for detecting acute ischemic stroke.

Authors:  Pengfei Li; Fengmeng Teng; Feng Gao; Mingshun Zhang; Jinping Wu; Chunbing Zhang
Journal:  Cell Mol Neurobiol       Date:  2014-11-20       Impact factor: 5.046

Review 6.  MicroRNAs expression and function in cerebral ischemia reperfusion injury.

Authors:  Yu Di; Yang Lei; Feng Yu; Fan Changfeng; Wang Song; Mo Xuming
Journal:  J Mol Neurosci       Date:  2014-04-04       Impact factor: 3.444

Review 7.  Regulation of pluripotency and differentiation by deubiquitinating enzymes.

Authors:  B Suresh; J Lee; H Kim; S Ramakrishna
Journal:  Cell Death Differ       Date:  2016-06-10       Impact factor: 15.828

8.  The Risk Versus Reward of Targeting Epileptogenic Signaling Pathways via miRNA Replacement Therapy.

Authors:  Heidi L Grabenstatter
Journal:  Epilepsy Curr       Date:  2016 Jul-Aug       Impact factor: 7.500

9.  The indirect NMDAR antagonist acamprosate induces postischemic neurologic recovery associated with sustained neuroprotection and neuroregeneration.

Authors:  Thorsten R Doeppner; Jens R Pehlke; Britta Kaltwasser; Jana Schlechter; Ertugrul Kilic; Mathias Bähr; Dirk M Hermann
Journal:  J Cereb Blood Flow Metab       Date:  2015-07-29       Impact factor: 6.200

10.  MicroRNA-124 negatively regulates LPS-induced TNF-α production in mouse macrophages by decreasing protein stability.

Authors:  Yang Sun; Zhen Qin; Qi Li; Jing-Jing Wan; Ming-He Cheng; Peng-Yuan Wang; Ding-Feng Su; Jian-Guang Yu; Xia Liu
Journal:  Acta Pharmacol Sin       Date:  2016-04-11       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.